Desk note · Yesterday · 4:20 p.m. ET
Hims is a growth story that keeps getting asked about profit.
The stock is higher with the consumer tape. The argument around it has not moved an inch.
Hims & Hers is the rare consumer name that shows up both in growth screens and in arguments about healthcare advertising. Today it is simply higher, in line with a firmer tape in discretionary health. That does not settle the margin question regular readers already know.
What we watch: customer acquisition cost when a category gets crowded, the mix between cash-pay and anything that looks like a benefit, and how management talks about new treatment lines. A single session’s percentage change is the least interesting of those.
The company stays on the radar because the product is legible — people understand a subscription for care — and because legible products attract both real users and very fast narratives. We would rather send one note when the cohort data changes than five notes when the stock does.
